Advancing Non-invasive
Healthcare with Nonacus

Non-invasive: the new healthcare

What is Nonacus?

Nonacus translates research into routine diagnostic tools that directly benefit patients and scientists. Their non-invasive cell-free DNA solutions improve diagnostic accuracy as well as the patient’s experience. With research & development team, they are constantly developing, validating and testing new cfDNA products

PRE-ANALYTICAL HEALTHCARE

Every sample is precious and to get the most out of your sample when evaluating cell-free DNA it is really critical to have processed your samples correctly from  blood collection through to extracted cfDNA. Learn more about our Cell3 preserver blood tube and Cell3 Xtract kit below.

PRENATAL HEALTHCARE

 

Nonacus continues to develop innovative products to meet these exacting standards including tests for fetal rhesus-D genotyping, fetal fraction quantitation and single gene disorder testing.

ONCOLOGY


Nonacus is working with some of the brightest scientists and clinicians by providing a validated complete workflow for liquid biopsy analysis. With the ultimate goal of enabling better cancer care through earlier diagnosis, treatment stratification and monitoring.

CONSTITUTIONAL GENETICS

Nonacus have developed library preparation solutions for Next Generation Sequencing (NGS) that offer you the chance to consolidate these worklows into a single assay. Combining the analysis of SNV’s, indels and CNV’s into a single assay, they enable you to save time and resoures and still deliver a comprehensive report on constitutional abnormalities from one workflow.

VIRUS DETECTION

We enable testing laboratories to provide highly sensitive and accurate testing products for SARS-CoV-2. Our VirPath: SARS-CoV-2 Kit is CE-IVD marked and one of the few qRT-PCR assays to pass the stringent accuracy and sensitivity requirements set for general COVID-19 qRT-PCR testing in the UK, detecting all known variants of SARS-CoV-2.

Pre-Analytical

Cell3™ Preserver

Bead Xtract cfDNA Kit

Cell3™ Xtract

Cell3™ Preserver

Specialized cell-free DNA blood collection tubes

 

Pre-analytical blood collection tubes specifically for liquid biopsy, validated for collection of whole blood and stabilization of cfDNA and ctDNA for up to 15 days.

  • Longer cell stability

    Stabilizes whole blood for up to 15 days post blood draw, making Cell3™ Preserver tubes ideal for batching samples prior to countrywide or international shipping.

  • No glass breakages

    Plastic evacuated tubes reduce the chance of tube breakage during transport or centrifugation and are compatible with standard draw equipment.

  • Fully validated for cfDNA

    Validated for use in non-invasive applications, such as NIPT and liquid biopsy; and for multiple techniques like qPCR and NGS.

  • Increased lab efficiency

    Barcoded labels allow seamless integration with your existing automation and laboratory management systems.

Bead Xtract cfDNA Kit

Scalable, automatable cfDNA extraction

A flexible and efficient cfDNA extraction kit that uses paramagnetic beads to obtain high quality cfDNA from plasma or serum

  • Flexible and scalable cfDNA purification

    Bead Xtract cfDNA extraction is easily scalable to suit your laboratory needs with a range of input volumes from 0.5-10 ml and both manual and automated protocols.

  • Fully automated or manual protocol

    From lysis through to separation, the protocol can be fully automated and is compatible with most open-source liquid handlers.

  • Maximize cfDNA yield for every sample

    High binding capacity beads maximise cfDNA recovery and an elution volume as low as 30 µl ensures cfDNA is concentrated enough for downstream applications without the need for DNA vacuum concentration. 

  • Quality cfDNA output for applications such as NGS

    The cfDNA DNA extraction kit uses the reversible nucleic acid-binding properties of paramagnetic particles along with an optimised binding system that targets recovery of small cfDNA fragments and minimises gDNA contamination.

Cell3™ Xtract

An efficient cell-free DNA extraction kit

The Cell3™ Xtract enables fast and flexible cell-free DNA extraction (cfDNA) from a range of biological samples ensuring high quality cfDNA & ctDNA for research and clinical applications.

  • Fast and flexible

    Cell3™ Xtract has a simple and flexible protocol for cell-free DNA extraction that requires no specialist equipment and with just 90 minutes of processing time will speed up your extractions.

  • Maximise sample input

    Whether you are working with 1ml or 10ml you can extract all cfDNA in one extraction. With a small elution volume of just 35ul you can avoid the need for a DNA concentration step.

  • Supports multiple uses

    Isolate cfDNA from a wide range of sample types: plasma, cerebrospinal fluid (CSF), saliva and amniotic fluid.

  • Accurate quantification

    Efficient cell-free DNA extraction without carrier RNA ensures accurate quantification of your extracted cfDNA for sensitive downstream applications like NGS.

Prenatal Healthcare

Fetal RhD Blood Group Genotyping

Cell3™ : Custom NGS Panels

Cell3™ Direct: Fetal RhD Blood Group Genotyping Kit

Non-invasive fetal Rhesus D (RhD) screening

 

A simple and quick qPCR protocol requiring no cffDNA extraction, Cell3™ Direct offers non-invasive fetal RhD diagnosis from plasma samples.

  • Results in under 3 hours

    With no cffDNA extraction required and a simple qPCR protocol, it takes under 3 hours from sample receipt to result.

  • Less material required

    Using less than <0.25ml of plasma sample, this test leaves plenty of sample for other prenatal tests.

  • Flexible and fully validated

    A validated kit and flexible tube forSection 3mat enables laboratory processing on any qPCR machine.

  • Multi-target assay

    A multi-target approach delivers an assay suitable for all populations and intra assay concordance for increased sensitivity.

Cell3™ Target: Custom NGS Panels – Prenatal

Non-invasive prenatal genetic testing

 

Reliable targeted enrichment developed for prenatal testing and diagnosis using cell-free fetal DNA (cffDNA) or genomic DNA (gDNA).

  • Validated for cell-free and genomic DNA

    NGS enrichment developed for and validated on cell-free DNA as well as gDNA for prenatal applications like non-invasive prenatal diagnosis

  • Confidently detect fetal fraction in maternal blood

    QC validation guarantees uniformity of coverage which combined with error suppression technology ensures confident detection of even the lowest fetal fraction

  • Simple and rapid design process

    Our online panel design tool means you can design and optimise a panel in minutes and our novel rapid manufacture process means minimal time between design and delivery

  • Optimised for large and small panels

    Cell3™ Target enrichment has been optimised to deliver efficient target capture and unrivalled on-target performance regardless of panel size from 1 gene to 1,000.

Oncology

Bladder Cancer Panel

Cell3™ Pan-Cancer Panel

Cell3™ Target: Tumor Exome

Custom NGS Panels

Actionable Mutation

Custom Panels MRD

Cell3™ Target: Bladder Cancer Panel

Comprehensive NGS panel for translational and clinical research into urothelial bladder cancer (UBC)

 

Targeting 451 somatic mutations found in 96% of bladder cancer cases, this panel has the potential to offer a non-invasive alternative to cytoscopy via urinary DNA analysis.

  • Clinically relevant content for bladder cancer

    Detects 451 clinically relevant somatic mutations found in 96% of bladder cancer cases

  • Ultra-sensitive mutation detection

    Uses proven Cell3™ Target error suppression technology allowing confident and accurate calling of somatic mutations down to 0.1% VAF

  • Validated on cpDNA and ctDNA from urine

    Developed for and validated on genomic DNA from urinary cell-pellet (cpDNA) and ctDNA from urine.

  • A non-invasive alternative to cystoscopy

    Provides clinical and translational researchers with a viable non-invasive alternative to cystoscopy for profiling bladder cancer.

Cell3™ Target: Pan-Cancer

 

Comprehensive cancer mutation analysis providing robust calling of SNVs, indels and CNVs, as well as TMB and MSI across 524 oncogenes using a single NGS enrichment workflow.

  • One workflow for multiple biomarkers

    Detect all variant types including SNVs, CNVs and indels as well as TMB and MSI across 524 oncogenes in a single NGS enrichment.

  • Run cfDNA and FFPE samples

    Validated on cfDNA and FFPE samples, as well as gDNA, giving you the option of profiling either primary, metastatic or liquid biopsies.

  • Measure tumor genomic instability

    Confidently extrapolate tumor mutation burden (TMB) from panel sequencing data for immunotherapy response prediction.

  • An alternative to whole exome sequencing

    Simplified analysis and reduced costs make this targeted panel an attractive alternative to tumor whole exome sequencing (WES) for routine use.

Cell3™ Target: Custom NGS Panels – Oncology

 

Targeted resequencing using innovative Cell3™ Target technology to convert any type of DNA (cfDNA, gDNA, FFPE DNA) into libraries for NGS.

  • Validated for FFPE and ctDNA samples

    Developed for and validated on ctDNA, gDNA and FFPE DNA for oncology applications like early cancer detection and monitoring cancer post treatment.

  • Confidently call low frequency variants

    QC validation guarantees uniformity of coverage which combined with error suppression technology ensures confident calling of all mutations down to 0.1% VAF.

  • Simple and rapid custom design process

    Our online panel design tool means you can design and optimise a panel in minutes and our rapid manufacture process means minimal time between design and delivery.

  • Optimised for large and small panels

    Cell3™ Target enrichment has been optimised to deliver efficient target capture and unrivalled on target performance regardless of panel size from 1 gene to 1,000.

Cell3™ Target: Custom NGS Panels – Prenatal

 

Whole exome capture with extensive clinically relevant content for comprehensive primary tumor sequencing.

  • Tumor relevant content

    Whole exome capture designed specifically for cancer research covering key intronic regions like promoters, translocations and fusions and CNVs.

  • Range of sample types

    Our tumor exome supports a broad range of sample types, including formalin-fixed, paraffin-embedded (FFPE) DNA, FF, gDNA and cell-free DNA (cfDNA).

  • Optimised performance

    Delivering excellent uniformity of coverage, Cell3™ Target Tumor Exome reduces sequencing costs and improves sample throughput.

  • Customisable

    Designed to be flexible, Cell3™ Target Tumor Exome allows you to add extra content to cover targets specific to your project.

Cell3™ Target: Actionable Mutation Panel

 

Detect low frequency variants in key oncogenes of the Epidermal Growth Factor Receptor (EGFR) pathway using genomic DNA (gDNA) or cell free DNA (cfDNA) from primary tumours or liquid biopsies.

  • Clinically relevant content

    A highly focused panel covering the actionable mutations in key oncogenes in the EGFR pathway.

  • Primary tumor or liquid biopsy

    Developed for and validated on ctDNA as well as gDNA and FFPE giving you the option to profile primary tumors or liquid biopsies and matched samples.

  • Confidently call low frequency variants

    Cell3™ Target error suppression technology including unique molecular identifiers (UMIs), enables you to accurately call ultra-low frequency mutations down to 0.1% VAF.

  • Fast and affordable

    Using a focused panel simplifies analysis and reduces costs making this a fast and affordable method of profiling variants in the EGFR pathway.

Cell3™ Target: Custom Panels MRD

Longitudinal Monitoring for Minimal Residual Disease

 

Small, ultrasensitive, personalized NGS panels for detecting tumor specific variants at multiple time points

  • Personalized panels designed in minutes

    An on-line panel design tool and rapid manufacture process enables fast turnaround of highly targeted tumor specific NGS panels

  • Ultrasensitive tumor variant detection

    Confidently call mutations down to 0.1% variant allele frequency (VAF) from as little as 25 ng cell-free DNA (cfDNA).

  • Cost effective at high depth

    High on-target rates and superior uniformity of coverage, makes sequencing cost effective for depths of 20,000x and above.

  • Streamlined liquid biopsy workflow

    From sample collection through to sequencing, our liquid biopsy workflow provides a streamlined solution for longitudinal monitoring of MRD.  

Prenatal Healthcare

Cell3™ Target: Nexome

Cell3™ Target: ExomeCG

Whole Exome Enrichment

Carrier Screening Panel

Cell3™ Target: Nexome – a clinically enhanced exome panel

Detect SNVs, indels and CNVs in a single, clinical-grade assay

 

Capture more variants and increase your diagnostic yield without increasing your sequencing costs.

  • Clinically relevant content

    Maximise your diagnostic yield with coverage of important clinical targets from the major genetic databases including CNVs and non-coding regions associated with prenatal and postnatal disease.

  • Streamlined workflow

    Validate and run one workflow for all variants including SNVs, Indels and CNVs in a single, clinical-grade assay giving you the confidence to replace your array and MLPA-based CNV analysis.

  • Robust calling of variants

    Confidently call SNVs, indels and CNVs with high recall and precision from as little as 1 ng of DNA, unlocking prenatal or limited samples, without compromising on quality or robustness.

  • Maximise content, minimise sequencing costs

    Superior hybridization capture performance delivers significantly more content without increasing the amount of sequencing per sample or your sequencing costs.

Cell3™ Target: ExomeCG

Exome capture for cytogenomic analysis

 

Clinically enhanced human exome capture enabling detection of SNVs, indels and CNVs in a single assay.

  • Streamline your workflow

    ExomeCG lets you detect all variants (SNVs, indels and CNVs) in a single, clinical-grade assay, suitable for constitutional postnatal and prenatal analysis. Less handling. Less time. More results first time.

  • Clinically relevant genes

    The best coverage of clinical targets thanks to superior CNV detection at loci known to have both gene and exon-level rearrangements. Giving you the option to replace your array and MLPA-based CNV analysis.

  • Save time. Save resources

    Use as little as 1ng of DNA unlocking prenatal or limited samples and get results days earlier. ExomeCG saves you time and sample, without compromising on quality or robustness.

  • Software to support you

    ExomeCG fully integrates with the Congenica® clinical decision support platform for data visualisation and analysis. Combined with the Cell3™ Target range, we have your research needs covered, from start to finish.

Cell3™ Target: Whole Exome Enrichment

Whole exome sequencing

 

Optimised whole exome coverage delivering higher sample throughput and reducing sequencing costs.

  • Focused exonic content

    Our optimized exome covers 33Mb of highly-conserved protein coding regions and 99% of ClinVar variants, so you can focus on what matters.

  • Optimized performance

    Delivering excellent uniformity of coverage, Cell3™ Target Whole Exome minimises low coverage regions reducing sequencing costs and improving sample throughput

  • Range of sample types

    Cell3™ Target Whole Exome supports a broad range of sample types, including cell free, genomic and formalin-fixed, paraffin-embedded (FFPE) DNA.

  • Customisable

    Designed to be flexible, Cell3™ Target Whole Exome allows you to add extra content to cover targets specific to your project.

Cell3™ Target: Carrier Screening Panel

Carrier Screening for paediatric recessive disorders

 

Accurately analyse carrier status of 448 inherited childhood disorders using a single workflow.

  • Comprehensive content

    Designed to enrich for genes with high clinical significance in a broad range of rare, highly penetrant recessive childhood disorders

  • Streamlined workflow

    Consolidate multiple technology workflows into one simple NGS assay. No arrays. No MLPA.

  • Save time and resources

    One workflow saves you time and sample, without compromising on quality or robustness.

  • Cost effective

    Optimised so that as little 2.7Gb of data per sample is required to achieve accurate carrier status.

Virus Detection

VirPath: COVID-19 (SARS-CoV-2) Testing Products

VirPath: Respiratory Multiplex qRT-PCR Kit

VirPath: COVID-19 (SARS-CoV-2) Testing Products

 

Viral RNA extraction and qRT-PCR workflow for detection of COVID-19 (SARS-CoV-2) using our VirPath product range

We enable testing laboratories to provide highly sensitive and accurate testing products for SARS-CoV-2. Our VirPath: SARS-CoV-2 Kit is CE-IVD marked and one of the few qRT-PCR assays to pass the stringent accuracy and sensitivity requirements set for general COVID-19 qRT-PCR testing in the UK, detecting all known variants of SARS-CoV-2.

  • COVID-19 qRT-PCR kit

    Our VirPath SARS-CoV-2 Multiplex qRT-PCR Kit is CE-IVD marked and is one of the few COVID-19 qRT-PCR tests to pass the stringent accuracy and sensitivity requirements set for Government COVID-19 testing.

    To read our technical validation document from the Department of Health, please refer to the product resources section below.

  • Detects all known SARS-CoV-2 (COVID-19) variants

    There are now several SARS-CoV-2 variants, but rest assured, the overall sensitivity and accuracy of our VirPath Multiplex qRT-PCR test has not been impacted by the different SARS-CoV-2 variants.

    We continually monitor the public genomic databases for all new variants, so our customers can always be confident of our product performance.

     

     

      Differentiate COVID-19, flu and RSV in one assay

      VirPath: Respiratory Multiplex qRT-PCR Kit

       

      Highly sensitive and simple to use real-time RT-PCR assay designed for simultaneous detection of SARS-CoV-2, influenza type A/B and Respiratory syncytial virus (RSV) subtypes A and B.

      • True multiplex assay

        Streamline testing by detecting Flu A/B, RSV A/B and SARS-CoV-2 in a single, real time RT-PCR reaction

      • Workflow flexibility

        Choose the RNA extraction method and PCR thermocycler that fit with your workflow

      • Highly sensitive

        Detect as little as 5 copies of viral RNA per reaction and pick up infections with low viral load

      • Robust performance

        Have confidence in your results with an assay that targets conserved regions of SARS-CoV-2 and delivers minimal inter and intra assay variation.

      GALEAS™

      GALEAS™ Bladder

      GALEAS™ Hereditary Plus

      GALEAS Bladder

       

      A novel bladder cancer test providing a non-invasive, sample-to-report, molecular triage for patients with hematuria

      A NEW non-invasive NGS alternative to cystoscopy for ALL stages of bladder cancer

       

      GALEAS Bladder is a simple, sample-to-report urine test to detect the presence of bladder cancer. Developed in partnership with researchers at the University of Birmingham, UK, the test leverages ultra-sensitive targeted Next Generation Sequencing (NGS) to interrogate the key somatic mutations found across all grades and stages of bladder cancer.

      Delivering sensitivity of >90%, GALEAS Bladder allows urologists to make an informed, safe decision about determining which patients may need further investigation and which don’t.

       

       

          GALEAS Hereditary Plus 

          A clinically validated NGS panel with optimized bioinformatics for analyzing germline mutations associated with hereditary cancers – including Lynch syndrome.

           

          Complete hereditary cancer analysis at your fingertips. Streamline your testing from sample to data analysis.

           

          GALEAS HereditaryPlus is an innovative Next Generation Sequencing (NGS) panel that includes a meticulously curated collection of 146 genes well-established in their associations with hereditary cancer. The targeted gene list addresses not only key cancer syndromes like Lynch syndrome but also covers rarer hereditary cancer types like Phaeochromocytoma and pediatric cancers like Wilms tumor, ensuring a comprehensive understanding of the genetic landscape. The ability to target many types of cancer in one assay enables laboratories to streamline hereditary testing workflows.

           

           

              • Is a highly sensitive diagnostic test, equivalent to cystoscopy for all grades and stages of bladder cancer, including non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC).
              • Has the potential to be used across the whole bladder cancer care pathway including patient monitoring, relapse and minimal residual disease (MRD) surveillance as well as hematuria triage.
              • Uses a simple urine sample to investigate the presence of tumor-derived DNA.
              • Leverages ultra-sensitive targeted NGS chemistry developed by Nonacus, to detect 451 somatic mutations associated with bladder cancer.
              • Provides simple and quick reporting provided by the cloud-based GALEAS software, saving precious time when evaluating patient needs.

              The combination of careful design and state of the art bioinformatics pipelines supports the accurate detection of SNVs, indels and a wide range of CNVs without the need for additional testing with Sanger sequencing or Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. This innovative NGS panel provides unparalleled precision in hereditary cancer analysis regardless of variant type or cancer type.

              • SNVs: Delivers reliable identification of SNVs including direct genotyping of the MSH2 c.942+3A>T variant avoiding the need for Sanger sequencing and streamlining testing workflows.
              • INDELs: Accurately detects both small and large indels, including those exceeding 10 base pairs.
              • CNVs: Reliably and robustly identifies CNVs from single exons to whole genes and mosaic copy number variation potentially eliminating the need for MLPA in hereditary cancer testing.

              Contact us now!

              From customized bioinformatics analysis to innovative software tools, and Next Genereation Sequencing devices we provide everything you need to accelerate your research. Explore our services and products today. Contact us to schedule a meeting with our experts and achieve your research goals. Together, we can make a difference. 

              Expert Consultancy

              When you contact us, you can discover the most suitable solutions for your projects through one-to-one meetings with our expert consultants.

              Customized Services

              With services and products tailored specifically to your needs, we will accelerate your research processes and help you achieve your goals in less time.